A six-stage workflow for robust application of systems pharmacology

CPT: Pharmacometrics and Systems Pharmacology

Volumn 5, Issue 5, 2016, Pages 235-249

  Gadkar, K ^a   Kirouac, D C ^a   Mager, D E ^b   Van Der Graaf, P H ^c,d   Ramanujan, S ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

^d CERTARA UK LIMITED   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; BIOLOGY; DRUG DEVELOPMENT; DRUG RESEARCH; INFORMATION PROCESSING; MATHEMATICAL MODEL; MATHEMATICS; PHARMACEUTICS; PHARMACOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE AND SYSTEMS PHARMACOLOGY; SIMULATION; SYSTEMS BIOLOGY; TREATMENT OUTCOME; WORKFLOW; CLINICAL PHARMACOLOGY; DATABASE MANAGEMENT SYSTEM; HUMAN; PROCEDURES;

COMPUTATIONAL BIOLOGY; DATABASE MANAGEMENT SYSTEMS; HUMANS; PHARMACOLOGY, CLINICAL; SYSTEMS BIOLOGY; WORKFLOW;

EID: 84963512966     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12071     Document Type: Article

References (100)

1. Parker, R.S., & Doyle, F.J. 3rd. Control-relevant modeling in drug delivery. Adv. Drug Deliv. Rev. 48, 211-228 (2001
2. van der Graaf, P.H., & Benson, N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28, 1460-1464 (2011
3. Ramanujan, S., Kadambi, A., & Gadkar, K. Quantitative systems pharmacology: applications and adoption in the drug development industry. Systems Pharmacology and Pharmacodynamics. (eds. Mager, D., & Kimko, H) (Springer, New York, NY, 2015
4. Sorger, P.K., & Allerheiligen, S.R.B. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. An NIH White Paper by the QSP Workshop Group, October 2011
5. Rogers, M., Lyster, P., & Okita, R. NIH support for the emergence of quantitative and systems pharmacology. CPT Pharmacometrics Syst. Pharmacol. 2, e37 (2013
6. Peterson, M.C., & Riggs, M.M. FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment? CPT Pharmacometrics Syst. Pharmacol. 4, e00020 (2015
7. Visser, S.A., de Alwis, D.P., Kerbusch, T., Stone, J.A., & Allerheiligen, S.R. Implementation of quantitative and systems pharmacology in large pharma. CPT Pharmacometrics Syst. Pharmacol. 3, e142 (2014
8. Leil, T.A., & Bertz, R. Quantitative systems pharmacology can reduce attrition and improve productivity in pharmaceutical research and development. Front. Pharmacol. 5, 247 (2014
9. Vicini, P., & van der Graaf, P.H. Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan? Clin. Pharmacol. Ther. 93, 379-381 (2013
10. Friedrich, C.M. A model qualification method for mechanistic physiological QSP models to support model-informed drug development. CPT Pharmacometrics Syst. Pharmacol. 5, 43-53 (2016
11. Ghosh, S., Matsuoka, Y., Asai, Y., Hsin, K.Y., & Kitano, H. Software for systems biology: from tools to integrated platforms. Nat. Rev. Genet. 12, 821-832 (2011
12. Azeloglu, E.U., & Iyengar, R. Good practices for building dynamical models in systems biology. Sci. Signal. 8, fs8 (2015
13. Zhang, X.-Y. Trame, M.N., Lesko, L.J., & Schmidt, S. Sobol sensitivity analysis: a tool to guide the development and evaluation of systems pharmacology models. CPT Pharmacometrics Syst. Pharmacol. 4, 69-79 (2015
14. Rullmann, J.A., Struemper, H., Defranoux, N.A., Ramanujan, S., Meeuwisse, C.M., & van Elsas, A. Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. Syst. Biol. (Stevenage) 152, 256-262 (2005
15. Peterson, M.C., & Riggs, M.M. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 46, 49-63 (2010
16. Benson, N., et al. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus 3, 20120071 (2013
17. Gadkar, K., Budha, N., Baruch, A., Davis, J.D., Fielder, P., & Ramanujan, S. A mechanistic systems pharmacology model for prediction of LDL cholesterol lowering by PCSK9 antagonism in human dyslipidemic populations. CPT Pharmacometrics Syst. Pharmacol. 3, e149 (2014
18. Schoeberl, B., et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2, ra31 (2009
19. Rebholz-Schuhmann, D., Oellrich, A., & Hoehndorf, R. Text-mining solutions for biomedical research: enabling integrative biology. Nat. Rev. Genet. 13, 829-839 (2012
20. Ajmera, I., Swat, M., Laibe, C., Le Novere, N., & Chelliah, V. The impact of mathematical modeling on the understanding of diabetes and related complications. CPT Pharmacometrics Syst. Pharmacol. 2, e54 (2013
21. Kirouac, D.C., Saez-Rodriguez, J., Swantek, J., Burke, J.M., Lauffenburger, D.A., & Sorger, P.K. Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks. BMC Syst. Biol. 6, 29 (2012
22. Bauer-Mehren, A., Furlong, L.I., & Sanz, F. Pathway databases and tools for their exploitation: benefits, current limitations and challenges. Mol. Syst. Biol. 5, 290 (2009
23. Barretina, J., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012
24. Klijn, C., et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33, 306-312 (2015
25. Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120 (2013
26. Chelliah, V., et al. BioModels: ten-year anniversary. Nucleic Acids Res. 43(Database issue), D542-D548 (2015
27. Shoda, L.K., et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23, 115-126 (2005
28. Shoda, L., et al. The type 1 diabetes PhysioLab platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin. Exp. Immunol. 161, 250-267 (2010
29. Lu, D., et al. Model-based meta-Analysis for quantifying paclitaxel dose response in cancer patients. CPT Pharmacometrics Syst. Pharmacol. 3, e115 (2014
30. Ideker, T., & Lauffenburger, D. Building with a scaffold: emerging strategies for highto low-level cellular modeling. Trends Biotechnol. 21, 255-262 (2003
31. Birse, K., et al. Molecular signatures of immune activation and epithelial barrier remodeling are enhanced during the luteal phase of the menstrual cycle: implications for HIV susceptibility. J. Virol. 89, 8793-8805 (2015
32. Janes, K.A., Albeck, J.G., Gaudet, S., Sorger, P.K., Lauffenburger, D.A., & Yaffe, M.B. A systems model of signaling identifies a molecular basis set for cytokineinduced apoptosis. Science 310, 1646-1653 (2005
33. Jones, G., Darian-Smith, E., Kwok, M., & Winzenberg, T. Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate? Biologics 6, 155-161 (2012
34. Pavlopoulos, G.A., Wegener, A.L., & Schneider, R. A survey of visualization tools for biological network analysis. BioData Min. 1, 12 (2008
35. Saez-Rodriguez, J., Alexopoulos, L.G., Zhang, M., Morris, M.K., Lauffenburger, D.A.& Sorger, P.K. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res. 71, 5400-5411 (2011
36. Demir, E., et al. The BioPAX community standard for pathway data sharing. Nat. Biotechnol. 28, 935-942 (2010
37. Le Novere, N., et al. The systems biology graphical notation. Nat. Biotechnol. 27, 735-741 (2009
38. Lloyd, C.M., Halstead, M.D., & Nielsen, P.F. CellML: its future, present and past. Prog. Biophys. Mol. Biol. 85, 433-450 (2004
39. Terfve, C., et al. CellNOptR: a flexible toolkit to train protein signaling networks to data using multiple logic formalisms. BMC Syst. Biol. 6, 133 (2012
40. Chaouiya, C., et al. SBML qualitative models: a model representation format and infrastructure to foster interactions between qualitative modelling formalisms and tools. BMC Syst. Biol. 7, 135 (2013
41. Agoram, B. Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models. CPT Pharmacometrics Syst. Pharmacol. 3, e101 (2014
42. Schoeberl, B., Eichler-Jonsson C, Gilles ED, Muller G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat. Biotechnol. 20, 370-375 (2002
43. Hendrickx, D.M., Hendriks, M.M., Eilers, P.H., Smilde, A.K., & Hoefsloot, H.C. Reverse engineering of metabolic networks, a critical assessment. Mol. Biosyst. 7, 511-520 (2011
44. Alexopoulos, L.G., Saez-Rodriguez, J., Cosgrove, B.D., Lauffenburger, D.A., & Sorger, P.K. Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol. Cell Proteomics 9, 1849-1865 (2010
45. Sachs, K., Perez, O., Pe er, D., Lauffenburger, D.A., & Nolan, G.P. Causal proteinsignaling networks derived from multiparameter single-cell data. Science 308, 523-529 (2005
46. Liu, Z.P. Reverse engineering of genome-wide gene regulatory networks from gene expression data. Curr. Genomics 16, 3-22 (2015
47. Xing, H., et al. Causal modeling using network ensemble simulations of genetic and gene expression data predicts genes involved in rheumatoid arthritis. PLoS Comput. Biol. 7, e1001105 (2011
48. Kholodenko, B.N., Kiyatkin, A., Bruggeman, F.J., Sontag, E., Westerhoff, H.V., & Hoek, J.B. Untangling the wires: a strategy to trace functional interactions in signaling and gene networks. Proc. Natl. Acad. Sci. USA 99, 12841-12846 (2002
49. Eduati, F., De Las Rivas, J., Di Camillo, B., Toffolo, G., & Saez-Rodriguez, J. Integrating literature-constrained and data-driven inference of signalling networks. Bioinformatics 28, 2311-2317 (2012
50. Berger, S.I., & Iyengar, R. Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472 (2009
51. Liu, Y.Y., Slotine, J.J., & Barabási, A.L. Observability of complex systems. Proc. Natl. Acad. Sci. USA 110, 2460-2465 (2013
52. Park, J., & Barabási, A.L. Distribution of node characteristics in complex networks. Proc. Natl. Acad. Sci. USA 104, 17916-17920 (2007
53. Chudasama, V.L., Ovacik, M.A., Abernethy, D.R., & Mager, D.E. Logic-based and cellular pharmacodynamic modeling of bortezomib responses in U266 human myeloma cells. J. Pharmacol. Exp. Ther. 354, 448-458 (2015
54. Krumsiek, J., Polsterl, S., Wittmann, D.M., & Theis, F.J. Odefy-from discrete to continuous models. BMC Bioinformatics 11, 233 (2010
55. Missel, P.J., Horner, M., & Muralikrishnan, R. Simulating dissolution of intravitreal triamcinolone acetonide suspensions in an anatomically accurate rabbit eye model. Pharm. Res. 27, 1530-1546 (2010
56. Cilfone, N.A., Pienaar, E., Thurber, G.M., Kirschner, D.E., & Linderman, J.J. Systems pharmacology approach toward the design of inhaled formulations of rifampicin and isoniazid for treatment of tuberculosis. CPT Pharmacometrics Syst. Pharmacol. 4, e00022 (2015
57. Machado, D., Costa, R.S., Rocha, M., Ferreira, E.C., Tidor, B., & Rocha, I. Modeling formalisms in systems biology. AMB Express 1, 45 (2011
58. Melas, I.N., Kretsos, K., & Alexopoulos, L.G. Leveraging systems biology approaches in clinical pharmacology. Biopharm. Drug Dispos. 34, 477-488 (2013
59. Masoudi-Nejad, A., Bidkhori, G., Hosseini Ashtiani, S., Najafi, A., Bozorgmehr, J.H.& Wang, E. Cancer systems biology and modeling: microscopic scale and multiscale approaches. Semin. Cancer Biol. 30, 60-69 (2015
60. Aldridge, B.B., Saez-Rodriguez, J., Muhlich, J.L., Sorger, P.K., & Lauffenburger, D.A. Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. PLoS Comput. Biol. 5, e1000340 (2009
61. Janes, K.A., & Yaffe, M.B. Data-driven modelling of signal-Transduction networks. Nat. Rev. Mol. Cell Biol. 7, 820-828 (2006
62. Benedict, K.F., & Lauffenburger, D.A. Insights into proteomic immune cell signaling and communication via data-driven modeling. Curr. Top. Microbiol. Immunol. 363, 201-233 (2013
63. Gaebler, J.A., et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc. Health Risk Manag. 8, 255-264 (2012
64. Eddy, D., Schlessinger, L., Kahn, R., Peskin, B., & Schiebinger, R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care 32, 361-366 (2009
65. Morris, M.K., Saez-Rodriguez, J., Sorger, P.K., & Lauffenburger, D.A. Logic-based models for the analysis of cell signaling networks. Biochemistry 49, 3216-3224 (2010
66. Mei, Y., Carbo, A., Hoops, S., Hontecillas, R., & Bassaganya-Riera, J. ENISI SDE: a new web-based tool for modeling stochastic processes. IEEE/ACM Trans. Comput. Biol. Bioinform. 12, 289-297 (2015
67. Hwang, M., Garbey, M., Berceli, S.A., & Tran-Son-Tay, R. Rule-based simulation of multi-cellular biological systems-A review of modeling techniques. Cell Mol. Bioeng. 2, 285-294 (2009
68. Jiao, Y., & Torquato, S. Emergent behaviors from a cellular automaton model for invasive tumor growth in heterogeneous microenvironments. PLoS Comput. Biol. 7, e1002314 (2011
69. Monteagudo, Á., & Santos, J. Studying the capability of different cancer hallmarks to initiate tumor growth using a cellular automaton simulation. Application in a cancer stem cell context. Biosystems 115, 46-58 (2014
70. Read, M., et al. Determining disease intervention strategies using spatially resolved simulations. PLoS One 8, e80506 (2013
71. Mallet, D.G., & De Pillis, L.G. A cellular automata model of tumor-immune system interactions. J. Theor. Biol. 239, 334-350 (2006
72. Kim, P.S., & Lee, P.P. Modeling protective anti-Tumor immunity via preventative cancer vaccines using a hybrid agent-based and delay differential equation approach. PLoS Comput. Biol. 8, e1002742 (2012
73. Woodhead, J.L., et al. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front. Pharmacol. 5, 240 (2014
74. Pichardo-Almarza, C., Metcalf, L., Finkelstein, A., & Diaz-Zuccarini, V. Using a systems pharmacology approach to study the effect of statins on the early stage of atherosclerosis in humans. CPT Pharmacometrics Syst. Pharmacol. 4, e00007 (2015
75. Gutenkunst, R.N., Waterfall, J.J., Casey, F.P., Brown, K.S., Myers, C.R., & Sethna, J.P. Universally sloppy parameter sensitivities in systems biology models. PLoS Comput. Biol. 3, 1871-1878 (2007
76. Marino, S., Hogue, I.B., Ray, C.J., & Kirschner, D.E. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 254, 178-196 (2008
77. Sobie, E.A. Parameter sensitivity analysis in electrophysiological models using multivariable regression. Biophys. J. 96, 1264-1274 (2009
78. Huang, C.Y., & Ferrell, J.E. Jr. Ultrasensitivity in the mitogen-Activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 93, 10078-10083 (1996
79. Kholodenko, B.N. Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-Activated protein kinase cascades. Eur. J. Biochem. 267, 1583-1588 (2000
80. Qiao, L., Nachbar, R.B., Kevrekidis, I.G., & Shvartsman, S.Y. Bistability and oscillations in the Huang-Ferrell model of MAPK signaling. PLoS Comput. Biol. 3, 1819-1826 (2007
81. Okino, M.S., & Mavrovouniotis, M.L. Simplification of mathematical models of chemical reaction systems. Chem. Rev. 98, 391-408 (1998
82. Schmidt, H., Madsen, M.F., Danø, S., & Cedersund, G. Complexity reduction of biochemical rate expressions. Bioinformatics 24, 848-854 (2008
83. Schmidt, S., Post, T.M., Peletier, L.A., Boroujerdi, M.A., & Danhof, M. Coping with time scales in disease systems analysis: application to bone remodeling. J. Pharmacokinet. Pharmacodyn. 38, 873-900 (2011
84. Kearns, M., Mansour, Y., Ng, A.Y., & Ron, D. An experimental and theoretical comparison of model selection methods. Mach. Learn. 27, 7-50 (1997
85. Sébastien, H. An introduction to model selection: tools and algorithms. Tutor. Quant. Methods Psychol. 2, 1-10 (2006
86. Chou, I.C., & Voit, E.O. Recent developments in parameter estimation and structure identification of biochemical and genomic systems. Math. Biosci. 219, 57-83 (2009
87. Moles, C.G., Mendes, P., & Banga, J.R. Parameter estimation in biochemical pathways: a comparison of global optimization methods. Genome Res. 13, 2467-2474 (2003
88. Sun, J., Garibaldi, J.M., & Hodgman, C. Parameter estimation using meta-heuristics in systems biology: a comprehensive review. IEEE/ACM Trans. Comput. Biol. Bioinform. 9, 185-202 (2012
89. Rodriguez-Fernandez, M., Egea, J.A., & Banga, J.R. Novel metaheuristic for parameter estimation in nonlinear dynamic biological systems. BMC Bioinformatics 7, 483 (2006
90. Lu, J., Hubner, K., Nanjee, M.N., Brinton, E.A., & Mazer, N.A. An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway. PLoS Comput. Biol. 10, e1003509 (2014
91. del Rosario, R.C., Mendoza, E., & Voit, E.O. Challenges in lin-log modelling of glycolysis in Lactococcus lactis. IET Syst. Biol. 2, 136-149 (2008
92. Polisetty, P.K., Voit, E.O., & Gatzke, E.P. Identification of metabolic system parameters using global optimization methods. Theor. Biol. Med. Model. 3, 4 (2006
93. Nayak, S., et al. Using a systems pharmacology model of the blood coagulation network to predict the effects of various therapies on biomarkers. CPT Pharmacometrics Syst. Pharmacol. 4, 396-405 (2015
94. Modchang, C., Triampo, W., & Lenbury, Y. Mathematical modeling and application of genetic algorithm to parameter estimation in signal transduction: trafficking and promiscuous coupling of G-protein coupled receptors. Comput. Biol. Med. 38, 574-582 (2008
95. Kirouac, D.C., et al. Computational modeling of ERBB2-Amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci. Signal. 6, ra68 (2013
96. Gomez-Cabrero, D., Compte, A., & Tegner, J. Workflow for generating competing hypothesis from models with parameter uncertainty. Interface Focus 1, 438-449 (2011
97. Schmidt, B.J., Casey, F.P., Paterson, T., & Chan, J.R. Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis. BMC Bioinformatics 14, 221 (2013
98. Apgar, J.F., Witmer, D.K., White, F.M., & Tidor, B. Sloppy models, parameter uncertainty, and the role of experimental design. Mol. Biosyst. 6, 1890-1900 (2010
99. Maiwald, T., Kreutz, C., Pfeifer, A.C., Bohl, S., Klingmuller, U., & Timmer, J. Dynamic pathway modeling: feasibility analysis and optimal experimental design. Ann. NY Acad. Sci. 1115, 212-220 (2007
100. Videla, S., et al. Designing experiments to discriminate families of logic models. Front. Bioeng. Biotechnol. 3, 131 (2015